Physician profile
Jonathan Le
NPI 1982089892
$2,643.26
in general payments reported to CMS, 2019-2025
12 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $55.03 · 2021: $425 · 2022: $485 · 2023: $843 · 2024: $203 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112 · Entertainment: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.40 |
| Entertainment | $166.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $820.16 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $334.15 | 2022-2024 | Miebo, Lotemax Sm, Prolensa |
| Allergan, INC. | $288.34 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.04 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $167.69 | 2019-2021 | |
| Optos, INC. | $166.34 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $144.06 | 2023 | |
| Glaukos Corporation | $143.16 | 2025 | Istent Infinite, Idosetr |
| Shire North American Group INC | $118.16 | 2019 | |
| Horizon Therapeutics Plc | $115.75 | 2022 | |
| Alcon Vision LLC | $102.73 | 2019-2025 | Total30, Simbrinza |
| Oyster Point Pharma, INC. | $61.68 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.